Brendan Eckelman, Ph.D.

Brendan Eckelman, Ph.D.

Co-founder, Chief Operating Officer and Vice President of Biotherapeutics, Inhibrx LP

Brendan is co-founder of the small biotech company Inhibrx, which is quickly developing drugs that span oncology, infectious disease and inflammatory conditions. He leads therapeutic development and scientific operations, along with holding critical responsibilities in corporate strategy execution. That’s no small task considering Inhibrx plans to file seven INDs in the next 18 months. After earning his Ph.D. in molecular pathology from UCSD School of Medicine, Brendan performed graduate research at Sanford Burnham Prebys Medical Discovery Institute and before joining the Genomics Institute of the Novartis Research Foundation as a research investigator. Now at Inhibrix, he’s focused on keeping the innovation engine churning, free of bureaucratic barriers. The end goal: “Annually advance multiple new therapeutics into clinical development, which are capable of surpassing the ever-raising efficacy bar.”